Oral VK2735 and the SUNRISE trials
Oral VK2735 is Viking Therapeutics' investigational tablet formulation of a GLP-1/GIP receptor agonist. Viking announced its SUNRISE Phase 3 program on October 14 and discussed it again on October 28. A Phase 3 program announcement describes a development milestone, not an approved product or a completed efficacy result. 1 2
What are SUNRISE-1 and SUNRISE-2?
Viking describes two randomized, double-blind, placebo-controlled trials with 68 weeks of treatment and planned enrollment of 560 participants each. SUNRISE-1 concerns adults with obesity or qualifying overweight without type 2 diabetes; SUNRISE-2 concerns people with type 2 diabetes. 1
| Program | Formulation and question |
|---|---|
| SUNRISE | Oral VK2735; weight-management trials over 68 weeks |
| VANQUISH | Subcutaneous VK2735; a separate Phase 3 program |
| Maintenance studies | Separate studies of maintaining prior weight reduction |
What does the registry currently show?
The SUNRISE-1 record, NCT07868835, lists planned enrollment of 560 and percentage weight change at week 68 as its primary outcome. The snapshot checked on November 5 was last posted October 16 and still marked not yet recruiting, with an estimated November start. 3
That differs in wording from the sponsor's later description of the program as underway. A trial-program announcement and a site's recruitment status are different records. The dated registry should be checked directly before making a claim about enrollment or participation.
Are the earlier oral results the Phase 3 results?
No. The October announcements summarize earlier oral VENTURE research while introducing SUNRISE. Results from a shorter prior-phase study do not become Phase 3 outcomes when a later trial begins. 1 2
Keep the trial name beside any reported weight-change percentage. Then check whether the source describes oral or injectable material, the follow-up duration, the comparator and the population. This prevents results from different parts of the same development program being combined into an inaccurate headline.
Is the oral maintenance study a weekly pill study?
Viking's October 14 release contains a correction to its October 6 maintenance announcement: the oral maintenance option being evaluated is daily, not weekly. The correction concerns the study description, not instructions for using an available medicine. 1
That correction is a good reason to use the current issuer release instead of repeating an older summary. Maintenance after prior weight reduction is also a different research question from weight reduction measured from the start of a treatment trial.
What should the next update establish?
The useful next evidence is actual Phase 3 reporting, including participant flow, prespecified endpoints, adverse events, discontinuations and the analysis population. Regulatory status must be established separately from clinical results.
VK2735's oral and injectable programs share a compound name, but each formulation and study needs its own evidence. This report does not describe a product available for prescribing or suggest that a laboratory material is equivalent to a trial tablet.
Scope for European readers
This is a dated account of the research or policy described in the linked sources. The stated jurisdiction, study product and population matter. A US or UK announcement does not establish authorisation or availability across Europe. Nothing in this report establishes results for an EPS catalogue material. Read the research-use statement for the storefront's scope.